We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > GOCOVRI

News List

Adamas Completes Acquisition of OSMOLEX ER americanpharmaceuticalreview
January 14, 2021
Adamas Pharmaceuticals announced the closing of the settlement of patent litigation with Osmotica Pharmaceutical, a subsidiary of Osmotica Pharmaceuticals and completes the acquisition of the global rights to OSMOLEX ER®.
Adamas Announces FDA Filing Acceptance of sNDA to Modify Indication Statement for GOCOVRI americanpharmaceuticalreview
June 16, 2020
Adamas Pharmaceuticals announced its supplemental New Drug Application (sNDA) for GOCOVRI as a treatment for OFF episodes in Parkinson’s disease (PD) patients receiving levodopa-based therapy ...
Adamas Announces Patent for GOCOVRI in Parkinson’s Disease americanpharmaceuticalreview
May 19, 2020
Adamas Pharmaceuticals has been issued a new patent (no. 10,646,456) by the United States Patent and Trademark Office (USPTO) that covers GOCOVRI® (amantadine) extended release capsules.
Adamas Announces Settlement of Patent Litigation with Sandoz americanpharmaceuticalreview
January 03, 2020
Adamas has entered into a Settlement Agreement with Sandoz resolving its ongoing litigation concerning Sandoz’s Abbreviated New Drug Application (ANDA) seeking approval by ...